Motoo Y, Watanabe H, Yamaguchi Y, Mouri I, Fujii T, Yamakawa O, Satomura Y, Okai T, Sawabu N
Department of Internal Medicine, Kanazawa University, Japan.
Anticancer Res. 1996 Jul-Aug;16(4A):2041-8.
Urinary gonadotropin peptide (UGP) has been measured in gynecological and urological cancers, but its usefulness in the diagnosis of cancers of digestive organs has not been investigated. In this report, UGP was measured by sandwich enzyme immunoassay in 311 patients, including 166 patients with cancers of digestive organs and 43 healthy controls. Positive rates of UGP in various cancers of digestive organs were as follows: biliary tract 61.5%, pancreas 61.5%, esophagus 50.0%, liver 38.7%, colon and rectum 24.2%, and stomach 23.9%. The positive rate of UGP in benign diseases was 8.1%, and most false-positive patients were postmenopausal females. Positive rates of UGP were increased at advanced stages of gastric cancers, and UGP was decreased after tumor resection. From these results, it is suggested that UGP can be used as a tumor marker for the cancers of digestive organs.
尿促性腺激素肽（UGP）已在妇科和泌尿系统癌症中进行检测，但尚未研究其在消化器官癌症诊断中的效用。在本报告中，采用夹心酶免疫分析法对311例患者进行了UGP检测，其中包括166例消化器官癌症患者和43例健康对照者。UGP在各种消化器官癌症中的阳性率如下：胆道61.5%、胰腺61.5%、食管50.0%、肝脏38.7%、结肠和直肠24.2%、胃23.9%。UGP在良性疾病中的阳性率为8.1%，大多数假阳性患者为绝经后女性。UGP在胃癌晚期的阳性率升高，肿瘤切除后UGP降低。从这些结果来看，提示UGP可作为消化器官癌症的肿瘤标志物。
